Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 972 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Drug A (Blinded Drug) Clear all
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Black Forest Cocoa Flavanol Supplementation and Health Trial

NCT07747714
View directory record Official record
Conditions
Endothelial Function, Oxidative Stress, Inflamation, Vascular Health
Interventions
Cocoa Flavanol Supplement, Low-Flavanol Control Powder
Dietary Supplement
Lead sponsor
The Black Forest LLC
Industry
Eligibility
30 Years to 75 Years · Male only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Phase 2 Interventional Results available

Stellate Ganglion Block for COVID-induced Parosmia

NCT06253806
View directory record Official record
Conditions
COVID-19-Induced Parosmia
Interventions
Stellate Ganglion Block, Placebo Sham Injection
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients

NCT00002445
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
IM862
Drug
Lead sponsor
Cytran
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
31
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

NCT01002742
View directory record Official record
Conditions
Graft-versus-Host Disease, Immune System Disorders
Interventions
Mycophenolate Mofetil, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Not listed
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
36
States / cities
Duarte, California • La Jolla, California • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of a Bilateral TAP Block and Preperitoneal Instillation of Local Anesthetic for a Total Extraperitoneal (TEP) Repair

NCT02036983
View directory record Official record
Conditions
Bilateral Inguinal Hernia Repair
Interventions
Transversus abdominis plane block (TAP BLOCK), Instillation of surgical site with local anesthetic., Opioid IV medications (Control)
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 16, 2026, 9:28 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06309966
View directory record Official record
Conditions
Focal Epilepsy
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Peoria, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon

NCT02688270
View directory record Official record
Conditions
Raynaud's Phenomenon Secondary to Connective Tissue Disease
Interventions
Vascana (0.9% nitroglycerin cream), Vehicle Cream (placebo)
Drug
Lead sponsor
Covis Pharma S.à.r.l.
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Multiple Locations, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Phase 2Phase 3 Interventional Results available

17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies

NCT00163020
View directory record Official record
Conditions
Preterm Birth
Interventions
17-alpha-hydroxyprogesterone caproate injectable, Placebo
Drug
Lead sponsor
Obstetrix Medical Group
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Laguna Hills, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 16, 2026, 9:28 AM EDT
Recruiting Phase 2 Interventional

A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

NCT07244263
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Zasocitinib (Dose A), Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
15
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Phase 4 Interventional Results available

Minimal Opioid Use After Total Hip Replacement (THR)

NCT03090152
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Periarticular injection (Deep injection), Periarticular injection (Superficial injection), Bupivacaine, Placebo
Procedure · Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

NCT01797445
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa

NCT00558844
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Arikayce™ 560 mg, Placebo for 560 mg, Arikayce™ 70 mg, Arikayce™ 140 mg, Placebo for 70 mg / 140 mg
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
6 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 16, 2026, 9:28 AM EDT
Withdrawn Phase 2 Interventional

RCT of SPG Blocks for Post-dural Headache

NCT03560349
View directory record Official record
Conditions
Post-Dural Puncture Headache
Interventions
Lidocaine HCl Gel 2%, placebo gel
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 16, 2026, 9:28 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis

NCT02319616
View directory record Official record
Conditions
Toxic Epidermal Necrolysis
Interventions
Clobetasol 0.05% ointment, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
7 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2019 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Not applicable Interventional Results available

Postoperative Knee Strength Following Total Knee Replacement: A Double-Blinded Randomized Comparison Study

NCT01620047
View directory record Official record
Conditions
Total Knee Replacement, Primary Knee Arthroplasty
Interventions
Fentanyl, Ropivacaine
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

NCT00246012
View directory record Official record
Conditions
Melanoma
Interventions
Intetumumab, Dacarbazine, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
17
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Skin Refrigerant to Reduce the Pain Associated With IV Insertion

NCT02499965
View directory record Official record
Conditions
Pain
Interventions
Ethyl Chloride Topical Aerosol Anesthetic, Nature's Tears Sterile Water
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Phase 4 Interventional Results available

Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder

NCT01010204
View directory record Official record
Conditions
Smoking Cessation, Bipolar Disorder
Interventions
Varenicline, Placebo
Drug
Lead sponsor
K.N. Roy Chengappa
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
DuBois, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Phase 4 Interventional

Lidocaine Infusion for Pain Relief in Children Scheduled for Tonsillectomy and Adenoidectomy

NCT03902314
View directory record Official record
Conditions
Children, Only, Tonsillar Hypertrophy, Adenoid Hypertrophy
Interventions
Lidocaine Iv, Saline Solution
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
4 Years to 10 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

ED90 of 3% Chloroprocaine for Cervical Cerclage

NCT03805438
View directory record Official record
Conditions
Cerclage, Cervical
Interventions
Chloroprocaine Hcl 3% Inj
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Little Rock, Arkansas • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

NCT02760433
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab, Placebo
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat

NCT05154955
View directory record Official record
Conditions
Submental Fat
Interventions
10XB-101 Solution for Injection, 10XB-101 Vehicle Solution for Injection
Drug
Lead sponsor
10xBio, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Encino, California • San Diego, California • Rolling Meadows, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)

NCT00542178
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Hypoglycemic Agents, Standard glycemia control, Intensive BP treatment, Standard BP control, Fenofibrate, Simvastatin, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
3,472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 16, 2026, 9:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED)

NCT03298815
View directory record Official record
Conditions
Ocular Graft Versus Host Disease
Interventions
Amniotic Fluid Eye Drops (AFED), Saline Solution
Biological · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 16, 2026, 9:28 AM EDT